A Phase II Study of Nivolumab: A Multicenter, Open-Label, Single Arm Study in Malignant Pleural Mesothelioma (MERIT)

被引：10
|
作者：
Goto, Y. [1 ]
Okada, M. [2 ]
Kijima, T. [3 ]
Aoe, K. [4 ]
Kato, T. [5 ]
Fujimoto, N. [6 ]
Nakagawa, K. [7 ]
Takeda, Y. [8 ]
Hida, T. [9 ]
Kanai, K. [10 ]
Imamura, F. [11 ]
Oizumi, S. [12 ]
Takahashi, T. [13 ]
Takenoyama, M. [14 ]
Tanaka, H. [15 ]
Ohe, Y. [16 ]
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Hiroshima Univ, Hiroshima, Japan
[3] Hyogo Coll Med, Nishinomiya, Hyogo, Japan
[4] Natl Hosp Org Yamaguchi Ube Med Ctr, Ube, Yamaguchi, Japan
[5] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan
[6] Okayama Rosai Hosp, Asbestos Study Ctr, Okayama, Japan
[7] Kinki Univ, Fac Med, Med Oncol, Osaka, Japan
[8] Natl Ctr Global Hlth & Med, Resp Med, Tokyo, Japan
[9] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[10] Wakayama Med Univ, Wakayama, Japan
[11] Osaka Int Canc Inst, Dept Gen Thorac Surg, Osaka, Japan
[12] Natl Hosp Org Hokkaido Canc Ctr, Dept Resp Med, Sapppro, Japan
[13] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan
[14] Kyushu Natl Canc Ctr, Dept Thorac Oncol, Fukuoka, Fukuoka, Japan
[15] Niigata Canc Ctr Hosp, Internal Med, Niigata, Japan
[16] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
malignant pleural mesothelioma; Nivolumab; PD-1;
D O I：
10.1016/j.jtho.2017.09.634
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA 19.01
引用
收藏
页码：S1883 / S1883
页数：1
相关论文
共 50 条
  • [21] Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)
    Nathan, Paul
    Ascierto, Paolo A.
    Haanen, John
    Espinosa, Enrique
    Demidov, Lev
    Garbe, Claus
    Guida, Michele
    Lorigan, Paul
    Chiarion-Sileni, Vanna
    Gogas, Helen
    Maio, Michele
    Fierro, Maria Teresa
    Hoeller, Christoph
    Terheyden, Patrick
    Gutzmer, Ralf
    Guren, Tormod K.
    Bafaloukos, Dimitrios
    Rutkowski, Piotr
    Plummer, Ruth
    Waterston, Ashita
    Kaatz, Martin
    Mandala, Mario
    Marquez-Rodas, Ivan
    Munoz-Couselo, Eva
    Dummer, Reinhard
    Grigoryeva, Elena
    Young, Tina C.
    Schadendorf, Dirk
    EUROPEAN JOURNAL OF CANCER, 2019, 119 : 168 - 178
  • [22] Intrapleural infusion of activated macrophages and γ-interferon in malignant pleural mesothelioma -: A phase II study
    Monnet, I
    Breau, JL
    Moro, D
    Lena, H
    Eymard, JC
    Ménard, O
    Vuillez, JP
    Chokri, M
    Romet-Lemonne, JL
    Lopez, M
    CHEST, 2002, 121 (06) : 1921 - 1927
  • [23] The activity of raltitrexed (Tomudex®) in malignant pleural mesothelioma:: an EORTC phase II study (08992)
    Baas, P
    Ardizzoni, A
    Grossi, F
    Nackaerts, K
    Numico, G
    Van Marck, E
    van de Vijver, M
    Monetti, F
    Smid-Geirnaerdt, MJA
    van Zandwijk, N
    Debruyne, C
    Legrand, C
    Giaccone, G
    EUROPEAN JOURNAL OF CANCER, 2003, 39 (03) : 353 - 357
  • [24] Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)
    C. Raynaud
    L. Greillier
    J. Mazieres
    I. Monnet
    B. Mastroianni
    G. Robinet
    G. Fraboulet
    A. Dixmier
    H. Berard
    R. Lamy
    J. Letreut
    H. Lena
    G. Oliviero
    S. Botta
    A. Vergnenegre
    I. Borget
    C. Chouaid
    BMC Cancer, 15
  • [25] Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)
    Raynaud, C.
    Greillier, L.
    Mazieres, J.
    Monnet, I.
    Mastroianni, B.
    Robinet, G.
    Fraboulet, G.
    Dixmier, A.
    Berard, H.
    Lamy, R.
    Letreut, J.
    Lena, H.
    Oliviero, G.
    Botta, S.
    Vergnenegre, A.
    Borget, I.
    Chouaid, C.
    BMC CANCER, 2015, 15
  • [26] An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas
    Chen, Ming-Huang
    Chou, Wen-Chi
    Hsiao, Chin-Fu
    Jiang, Shih Sheng
    Tsai, Hui-Jen
    Liu, Yi-Chang
    Hsu, Chiun
    Shan, Yans-Shen
    Hung, Yi-Ping
    Hsich, Chia-Hsun
    Chiu, Chao-Hua
    Liu, Ta-Chih
    Cho, Shih-Feng
    Liu, Tsang-Wu
    Chao, Yee
    ONCOLOGIST, 2020, 25 (05) : E782 - E788
  • [27] Paclitaxel for malignant pleural mesothelioma: A phase II study of the EORTC Lung Cancer Cooperative Group
    vanMeerbeeck, J
    Debruyne, C
    vanZandwijk, N
    Postmus, PE
    Pennucci, MC
    vanBreukelen, F
    Galdermans, D
    Groen, H
    Pinson, P
    vanGlabbeke, M
    vanMarck, E
    Giaccone, G
    BRITISH JOURNAL OF CANCER, 1996, 74 (06) : 961 - 963
  • [28] Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma
    Watanabe, Kageaki
    Okuma, Yusuke
    Kawai, Shoko
    Nagamata, Makoto
    Hosomi, Yukio
    THORACIC CANCER, 2021, 12 (11) : 1668 - 1672
  • [29] Regorafenib plus nivolumab in patients with mismatch repair- proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study
    Fakih, Marwan
    Raghav, Kanwal Pratap Singh
    Chang, David Z.
    Larson, Tim
    Cohn, Allen L.
    Huyck, Timothy K.
    Cosgrove, David
    Fiorillo, Joseph A.
    Tam, Rachel
    D'Adamo, David
    Sharma, Neelesh
    Brennan, Barbara J.
    Wang, Ying A.
    Coppieters, Sabine
    Zebger-Gong, Hong
    Weispfenning, Anke
    Seidel, Henrik
    Ploeger, Bart A.
    Mueller, Udo
    de Oliveira, Carolina Soares Viana
    Paulson, Andrew Scott
    ECLINICALMEDICINE, 2023, 58
  • [30] CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trial
    Saunders, M. P.
    Graham, J.
    Cunningham, D.
    Plummer, R.
    Church, D.
    Kerr, R.
    Cook, S.
    Zheng, S.
    La Thangue, N.
    Kerr, D.
    ESMO OPEN, 2022, 7 (06)
12345